The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10623 malaria professionals are enjoying the free benefits of MalariaWorld today

CQ-PQ

Polymorphisms in Plasmodium vivax antifolate resistance markers in Afghanistan between 2007 and 2017

July 15, 2020 - 15:13 -- Open Access
Author(s): 
Kasama Rakmark, Ghulam R. Awab, Jureeporn Duanguppama, Usa Boonyuen, Arjen M. Dondorp and Mallika Imwong
Reference: 
Malaria Journal 2020 19:251, 14 July 2020

Plasmodium vivax is the predominant Plasmodium species in Afghanistan. National guidelines recommend the combination of chloroquine and primaquine (CQ-PQ) for radical treatment of P. vivax malaria. Artesunate in combination with the antifolates sulfadoxine-pyrimethamine (SP) has been first-line treatment for uncomplicated falciparum malaria until 2016. Although SP has been the recommended treatment for falciparum and not vivax malaria, exposure of the P. vivax parasite population to SP might still have been quite extensive because of community based management of malaria. The change in the P. vivax antifolate resistance markers between 2007 and 2017 were investigated.

Subscribe to RSS - CQ-PQ